[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vulvar-lichen-sclerosus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vulvar-lichen-sclerosus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,76,106,130,154,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100627591","efficacy-of-collagendep-in-reducing-vulvar-dryness-in-patients-with-lichen-sclerosus-treated-with-fat-grafting-100627591",false,"NCT07450625","Efficacy of Collagendep in Reducing Vulvar Dryness in Patients With Lichen Sclerosus Treated With Fat Grafting","Study of the Efficacy of Collagendep in Reducing Vulvar Dryness in Patients With Genital Lichen Sclerosus Treated With Fat Grafting","Collagendep","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Clinical diagnosis of Genital Lichen Sclerosus.\n* Patients with a clinical indication for autologous fat grafting (lipofilling) treatment.\n* Ability to provide written informed consent.\n* Willingness to comply with the study protocol and attend all scheduled follow-up visits.\n\nExclusion Criteria:\n\n* Presence of active local or systemic infections.\n* Current pregnancy or breastfeeding.\n* Known hypersensitivity or allergy to any of the ingredients of the study product \"Collagendep Pink Beauty\" (e.g., collagen, hyaluronic acid, herbal extracts).\n* Concurrent use of other oral supplements that might interfere with the evaluation of the study results.\n* Patients with oncological pathologies (malignancies) in the vulvar area.\n* Inability to guarantee adequate follow-up or compliance with the treatment regimen.","FEMALE","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, interventional study evaluates the efficacy of Collagendep Pink Beauty, an oral nutritional supplement, in reducing vulvar dryness in women with Genital Lichen Sclerosus (VLS) who are undergoing fat grafting treatment. Lichen sclerosus is a chronic inflammatory condition that leads to tissue hardening, loss of elasticity, and significant symptoms such as itching, pain, and dryness, which severely impact functional and emotional well-being. While fat grafting is a recognized regenerative therapy for stabilizing the disease, this study investigates whether a 4-month course of bioactive collagen peptides and functional ingredients can further improve mucosal hydration and symptom relief compared to fat grafting alone.",[27,28],"Vulvar Lichen Sclerosus","Vulvar Atrophy",[30,31,32,33,34,35],"Lichen Sclerosus","Regenerative Medicine","Collagen Peptides","Vulvar Dryness","Hyaluronic Acid","Sexual Function","NOT_YET_RECRUITING","2026-02-27",{"date":39,"type":40},"2026-03-04","ACTUAL",{"date":42,"type":21},"2026-02-20",{"date":44,"type":21},"2027-02-20",{"name":46,"class":47},"San Gallicano Dermatological Institute IRCCS","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100620076","phase-2-methotrexate-for-severe-vulvar-lichen-sclerosus-100620076","NCT07352917","Methotrexate for Severe Vulvar Lichen Sclerosus","A Prospective Phase II Open-Label Pilot Study Evaluating the Efficacy and Safety of Methotrexate in the Treatment of Severe Vulvar Lichen Sclerosus","GRAVES-MTX","Inclusion Criteria:\n\n* Clinical diagnosis of genital lichen sclerosus et atrophicus (vulvar, perineal, or perianal);\n* Histopathological diagnosis of genital lichen sclerosus et atrophicus;\n* Disease severity defined according with a score above 24 on the Vulvar Quality of Life Index (VQLI);\n* Failure of symptom regression or progressive genital deformity after at least 3 months of treatment with a high-potency topical corticosteroid;\n* Normal baseline laboratory evaluation, including complete blood count, liver and kidney function tests, and negative serologies for HIV and hepatitis B and C;\n* For women of childbearing potential, a negative pregnancy test at screening.\n\nExclusion Criteria (assessed before signing the Informed Consent Form):\n\n* Lack of full mental or psychiatric capacity;\n* Need for assistance from a third party (legal guardian) to participate in the study;\n* Significant difficulty in understanding or expressing oneself in Portuguese;\n* Unavailability or inability to complete Likert-scale questionnaires;\n* Inability to comply with study requirements, including adherence to the treatment schedule and attendance at follow-up visits;\n* Unrealistic expectations regarding treatment benefits or the possibility of adverse effects;\n* Intention to become pregnant during the study period;\n* Refusal to adopt at least one adequate contraceptive method (hormonal or barrier) in women of childbearing potential;\n* Poor adherence to the commitment to abstain from alcoholic beverages;\n* Uncontrolled autoimmune comorbidities;\n* Refusal to sign the Informed Consent Form after adequate explanation and clarification of doubts;\n* Any indication of inability to comply with the conditions established in the research protocol. Decisions will be made to ensure participant safety and study integrity, with appropriate communication regarding the reasons for exclusion.\n\nExclusion Criteria (assessed after signing the Informed Consent Form):\n\n* Elevation of liver enzymes above normal limits or impaired renal function during laboratory monitoring. Exclusion refers to discontinuation of the experimental intervention; however, the participant will continue to receive comprehensive medical follow-up as needed;\n* Pregnancy. The participant will be withdrawn from the study intervention and referred for obstetric care, while continuing to receive medical follow-up;\n* Lack of cooperation, failure to attend scheduled follow-up visits, or failure to undergo required laboratory monitoring;\n* Any other condition that limits the participant's ability to comply with study procedures, as determined by the responsible investigator.",{"count":57,"type":21},12,[59],"PHASE2","Vulvar lichen sclerosus is a chronic inflammatory skin disease affecting the vulva and genital region, which may cause intense pruritus, pain, burning sensations, and progressive scarring. In severe cases, the disease may lead to significant anatomical changes, sexual dysfunction, and a reduction in quality of life.\n\nFirst-line treatment for vulvar lichen sclerosus consists of high-potency topical corticosteroids. Although many patients experience symptom relief, a considerable number of women continue to have persistent symptoms or progressive anatomical damage. For these patients, therapeutic options are limited.\n\nMTX is an immunomodulatory medication that has been used for several decades in the treatment of inflammatory and autoimmune diseases. Previous clinical observations suggest that MTX may be beneficial for patients with severe or treatment-resistant vulvar lichen sclerosus; however, prospective clinical studies in this population remain scarce.\n\nThis prospective, open-label, phase II pilot study aims to evaluate the efficacy and safety of subcutaneous injectable MTX, administered once weekly at a standardized initial dose of 12.5 mg, in women with severe vulvar lichen sclerosus who have not responded adequately to standard topical therapy. Participants will receive treatment for 12 months, with regular clinical and laboratory monitoring.\n\nThe primary objective of the study is to assess whether treatment with MTX leads to improvement in symptoms and stabilization of vulvar skin changes, using patient-reported outcome measures and standardized clinical assessments. Secondary objectives include evaluation of treatment tolerability, adherence, and the occurrence of adverse events.\n\nAs a pilot study, this research is designed to generate preliminary data on feasibility, safety, and potential clinical benefit, which may guide future larger controlled studies and contribute to the development of evidence-based therapeutic strategies for women with severe vulvar lichen sclerosus.",[27],[63,64,65],"Vulvar lichen sclerosus","Quality of life","methotrexate","RECRUITING","2026-01-21",{"date":69,"type":40},"2026-01-22",{"date":67,"type":40},{"date":72,"type":21},"2027-01",{"name":74,"class":47},"Clinica Dermatologica Arbache ltda",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":75},"100620908","dynamic-quadripolar-radiofrequency-vs-topical-corticosteroids-in-women-with-vulvar-lichen-sclerosus-100620908","NCT07363733","Dynamic Quadripolar Radiofrequency VS Topical Corticosteroids in Women With Vulvar Lichen Sclerosus","Randomized Clinical Trial of the Efficacy of Combined Dynamic Quadripolar Radiofrequency Therapy VS Topical Corticosteroid Therapy in Women With Vulvar Lichen Sclerosus","Inclusion Criteria:\n\n* Women aged 18 to 49 years (women of reproductive age);\n* Histologically confirmed diagnosis of vulvar lichen sclerosus;\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnancy or lactation;\n* Malignancy at the time of treatment or during any period of follow-up;\n* Postmenopausal status;\n* Severe decompensated somatic disease;\n* Sexually transmitted infections, including hepatitis B, hepatitis C, and syphilis;\n* Presence of a cardiac pacemaker or metal-containing intrauterine device (IUD);\n* History of treatment with other high-energy-based modalities within the last 6 months;\n* Use of topical corticosteroids within the last 3 months;\n* Immunosuppression, including immunodeficiency disorders (such as HIV\u002FAIDS) or use of immunosuppressive medications;\n* Psychiatric disorders or communication difficulties that may interfere with study participation or compliance.","49 Years",{"count":85,"type":21},68,[24],"This is a prospective, randomized study in women of reproductive age with vulvar lichen sclerosus. Participants will be randomly assigned by investigators using a computer-generated sequence to receive either combined dynamic quadripolar radiofrequency (DQRF) plus topical corticosteroid therapy or topical high-potency corticosteroid therapy alone. Clinical outcomes, patient-reported outcomes and tissue-level changes evaluated by histology, elastin histochemistry, and immunohistochemistry for estrogen, androgen receptors and superoxide dismutase 2 (SOD2) will be assessed before and after treatment, and during follow-up at 3, 6, and 12 months. Safety will be monitored throughout the study. Histochemical and immunohistochemical analyses will be performed in a subset of 10 patients per group before the treatment and at 3 months after the completion of treatment.",[27],[90,91,92,93,94,95],"vulvar lichen sclerosus","Dynamic Quadripolar RadioFrequency","Glucocorticoids","Immunohistochemistry","Quality of Life","Female Sexual Function","2026-01-14",{"date":98,"type":40},"2026-01-23",{"date":100,"type":21},"2026-01",{"date":102,"type":21},"2027-02",{"name":104,"class":105},"Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare","OTHER_GOV",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":75},"100611433","to-compare-inflammatory-biomarkers-before-and-after-treatment-with-clobetasol-or-fractional-co2-laser-in-women-with-histologically-confirmed-vulvar-lichen-sclerosus-without-prior-corticosteroid-treatment-100611433","NCT07240519","To Compare Inflammatory Biomarkers Before and After Treatment With Clobetasol or Fractional CO2 Laser, in Women With Histologically Confirmed Vulvar Lichen Sclerosus, Without Prior Corticosteroid Treatment.","Vulvar Lichen Sclerosus: Expression of Inflammatory Markers in a Randomized Clinical Trial With Clobetasol Versus Laser","LASER","Inclusion Criteria: Women older than 21 years; histological diagnostic of vulvar lichen sclerosus and no previous treatment with topic corticoesteroid\n\nExclusion Criteria: Women that don't agree in taking part of the study; other concomitant vulvar diseases; pre malignant vulvar disease HPV dependent and independent; previous pelvic radiotherapy\n\n\\-","21 Years",{"count":20,"type":21},[24],"The present study is a Clinical trial that compares clobetasol ointment versus Fractional CO2 laser for vulvar lichen sclerosus (VLE) treatment confirmed by histology, with no previous treatment. Lichen sclerosus is a chronic inflamatory disease that affects the vulvar skin in the majority of cases, generally in peri and post menopause. The main symptom is pruritus, along with dispareunia and vulvar pain. If not treated, it can leads to vulvar anatomy distortion and altough small, there is risk of neoplastic transformation towards pre cancer and invasive vulvar cancer. Clobetasol ointment is the standard treatment, but prolonged use can cause some adverse effects, such as thinning the skin, fungal infections, and exacerbation of symptoms. Forty participants are being randomized to clobetasol group, three months with reducing frequency and the other group of participants, to fractional dioxid carbon (CO2) laser for three sessions four weeks apart. At the beggining and three months after the completion of each treatment, a punch biopsy will be taken for every participant. The principal aim is to compare some inflamatory biomarkers before and after each treatment and compare them by imunohistoquemestry at Imunology and Imunogenetic Laboratory in Fiocruz, Rio de janeiro, Brazil.\n\nSecondary outcomes include clinical response and changes in vulvar anatomy, assessed using the Sheinis \\& Selk questionnaire before and after each treatment, as well as the evaluation of some clinical aspects, such as improvement in itching, dyspareunia and appearance of the vulva, along with satisfaction with the treatment, using the Visual Analogue Scale (VAS) from 1 to 10.\n\nWith this study, the investigators want to know if fractional CO2 laser can reduce the inflammatory process and symptoms in vulvar lichen sclerosus such as itching, and if this could be an alternative treatment for this condition.",[27],[120,90],"CO2 laser","2025-11-20",{"date":123,"type":40},"2025-11-26",{"date":125,"type":40},"2022-06-22",{"date":127,"type":21},"2026-06",{"name":129,"class":47},"Universidade Federal do Rio de Janeiro",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":75},"100611423","treatment-of-vulvar-lichen-sclerosus-with-corticosteroid-ointment-calcineurin-inhibitor-ointment-and-platelet-rich-plasma-prp-therapy-100611423","NCT07240389","Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","Evaluation of Therapeutic Outcomes in Vulvar Lichen Sclerosus Treated With Corticosteroids, Calcineurin Inhibitors, and Platelet-rich Plasma (PRP).","VULIS-3T","Inclusion Criteria:\n\n1. Age 30 to 80 years.\n2. Clinical diagnosis of vulvar lichen sclerosus confirmed by histopathological examination.\n3. Ability and willingness to provide written informed consent for participation in the study.\n4. Ability to comply with study procedures, including questionnaire completion and follow-up visits at baseline, 3 months, and 6 months.\n\nExclusion Criteria:\n\n1. Lack of written informed consent to participate in the study.\n2. Prior treatment for vulvar lichen sclerosus (any systemic or topical therapy targeted at VLS).\n3. Current or past vulvar neoplasia, including vulvar intraepithelial neoplasia (VIN) or vulvar carcinoma.\n4. Other organic or dermatologic causes of vulvar symptoms that could interfere with diagnosis or outcome evaluation.\n5. Any condition that, in the opinion of the investigator, would interfere with study participation, follow-up, or accurate interpretation of results.","30 Years","80 Years",{"count":141,"type":21},45,[24],"Vulvar lichen sclerosus (VLS) is a chronic inflammatory skin condition that affects the vulvar area, often causing itching, burning, and pain, and may lead to scarring and narrowing of the vaginal opening. The condition significantly reduces the quality of life and may increase the risk of cancerous changes if left untreated.\n\nThis clinical study aims to evaluate and compare three commonly used treatment methods for women with biopsy-confirmed vulvar lichen sclerosus:\n\nTopical corticosteroid therapy (clobetasol propionate 0.05%),\n\nTopical calcineurin inhibitor therapy (pimecrolimus), and\n\nPlatelet-rich plasma (PRP) injections, which use the patient's own blood plasma rich in growth factors to support tissue healing.\n\nA total of 45 participants aged 30 to 80 years will be enrolled and assigned to one of the three treatment groups. The effectiveness of therapy will be assessed using standardized questionnaires about symptoms and quality of life, as well as microscopic evaluation of tissue samples before and after treatment.\n\nThe study seeks to determine whether platelet-rich plasma (PRP) can serve as a safe and effective first-line treatment option for vulvar lichen sclerosus and to improve our understanding of the best therapeutic approaches for this chronic disease.",[27],[27],"2025-11-16",{"date":121,"type":40},{"date":149,"type":21},"2025-12-01",{"date":151,"type":21},"2027-01-31",{"name":153,"class":47},"Milosz Pietrus",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100567035","phase-1-stratamgt-in-the-reduction-of-vulvar-lichen-sclerosus-ls-symptoms-100567035","NCT06662942","StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms","A Double Blind Placebo-controlled Trial of StrataMGT for the Management of Vulvar Lichen Sclerosus Symptoms.","LS","Inclusion Criteria:\n\n* Female, 18 years or older.\n* With a diagnosis of biopsy proven vulvar lichen sclerosus.\n* Signed written informed consent.\n* Willingness and ability to comply with the study requirements.\n* Subject must have a score of 10 or greater in the VQLI at screening.\n* Must be on a stable regimen of topical corticosteroids or topical calcineurin inhibitor for at least 2 months prior to the screening visit.\n* Women currently on a stable regimen of intravaginal estrogen therapy for at least 2 months may remain on the estrogen therapy throughout the study.\n* Women currently using topical estrogen therapy on the vulva must stop two weeks prior to enrolling in the study.\n* Women must have a culture negative for candidiasis or bacterial vaginosis at screening.\n\nExclusion Criteria:\n\n* Who are immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an uncontrolled malignant disease.\n* Who suffer from a topical or systemic infections (bacterial, viral or fungal) at the time of screening. Subjects who screen positive for either candidiasis or bacterial vaginosis at the screening visit may be treated and retested and may participate if the confirmatory test after treatment is negative. Any vulvovaginal infections during their participation in the study will be considered an adverse event. The subject will then stop the study IP and will be treated for the infection and may resume use of the IP 3 days after the last dose of medication for the infection. They will be discontinued from the study if they have two infections during the study.\n* Who have been diagnosed with lichen planus, psoriasis, intraepithelial neoplasia, or carcinoma of the vulva.\n* Who had received an investigational drug within four weeks prior to the study or who intend to use other investigational drugs during the course of this study.\n* Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study.\n* Who have a history of substance abuse or any factor, which limits the subject's ability to cooperate with the study procedures.\n* Who are uncooperative, known to miss appointments (according to subjects' records) and are unlikely to follow medical instructions or are not willing to attend regularly scheduled visits.",{"count":163,"type":21},100,[165],"PHASE1","This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.",[27],[169],"StrataMGT","2024-11-07",{"date":172,"type":40},"2024-11-08",{"date":174,"type":40},"2024-10-16",{"date":176,"type":21},"2025-10-16",{"name":178,"class":47},"Andrew T. Goldstein, MD",3,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":186,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":75},"100566915","phase-1-use-of-platelet-rich-plasma-from-cord-blood-vs-placebo-in-the-treatment-of-vulvar-lichen-sclerosus-100566915","NCT06661382","Use of Platelet Rich Plasma from Cord Blood Vs Placebo in the Treatment of Vulvar Lichen Sclerosus","Inclusion Criteria:\n\n* women with VLS (clinical\u002Fhistological diagnosis)\n* good health conditions\n* written informed consent signed and dated by the patient\n\nExclusion Criteria:\n\n* pregnancy\n* coagulopathies, platelet disorders, cardiovascular and\u002For respiratory diseases\n* ongoing major infections\n* previous vulvar surgery (e.g., lipostructure and\u002For previous PRP)",true,{"count":163,"type":21},[165,59],"Vulvar lichen Sclerosus (VLS) is a cutaneous-mucosal dermatosis that causes in the adult female vulvar itching and burning due to scratching abrasions. Dyspareunia is often associated . The areas most affected are the labia minora, the periclitoral area, the navicular dimple, and the perianal area. The placement of VLS in the context of immune-mediated dermatoses is the basis of the rationale for treatment with high potency topical corticosteroids. However, in some cases, local corticosteroid therapy is not sufficient resulting in a significant impact on the quality of life of the patient. This gives rise to the need to identify new treatments such as regenerative medicine.\n\nThe term PRP (Platelet Rich Plasma) is used to describe a blood product generated by a two-step centrifugation process of whole blood of a patient to produce a concentration of platelets in a small volume of plasma. PRP can be produced from autologous, homologous blood or from cord blood (CB-PRP).\n\nOur objective is to evaluate the efficacy of CB-PRP versus placebo in the treatment of VLS.",[27],"2024-10-25",{"date":193,"type":40},"2024-10-28",{"date":195,"type":40},"2023-01-24",{"date":197,"type":21},"2024-12-24",{"name":199,"class":47},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"]